An observational study in Cancer, sponsored by University Hospital, Caen. Completed at 1 site in France. Per ClinicalTrials.gov, last updated 2021-09-23.
Sponsored by University Hospital, Caen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Although PARP inhibitors (PARPi) have proved effective in treating many cancers, few patients receiving PARPi may experience rare but serious adverse events such as pancytopenia. Today, data about pancytopenia are scarce.
The objective was to investigate reports of pancytopenia adverse events related to PARPi, including olaparib, rucaparib, niraparib, talazoparib, veliparib and pamiparib using the World Health Organization's (WHO) pharmacovigilance database: VigiBase.
Here, investigators use the World Health Organization's (WHO) database of individual safety case reports, to identify cases of pancytopenia related to PARPi.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 200 is close to the median of 200 across 2,641 observational studies indexed under Neoplasms.
Browse Neoplasms studies →University Hospital, Caen is the lead sponsor of 514 studies on the registry; 84 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Cancer patients treated with PARPi and experiencing pancytopenia.
Inclusion Criteria:
Exclusion Criteria: chronology not compatible between the PARPi and adverse event.
All patients treated at least with 1 PARPi
Also known as: olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib
This study also gives Olaparib, Niraparib, Rucaparib. No intervention listed here names it: that was found by reading the record.
Pancytopenia reports related to PARPi.
Identification of the pancytopenia adverse event related to PARP inhibitors reported in the World Health Organization's (WHO) database of individual safety case reports.
Time frame: From inception to Feb, 2021
Description of the latency period since first PARPi exposure.
Time frame: From inception to Feb, 2021
Description of the fatality rate.
Time frame: From inception to Feb, 2021
Description of patients who experienced co-reported adverse events
Time frame: From inception to Feb, 2021
Ran from Feb 2021 to primary completion in Feb 2021, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.